drugset / Trial / NCT07428499
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
Non-randomizedParallel-groupDouble-blindTreatment
Summary
Study ADX-324-302 is an extension study for participants who complete the Phase 3 ADX-324-301 trial. The extension study will provide information about the safety and efficacy of additional dosing of ADX-324 in participants with Type I and Type II hereditary angioedema (HAE). The study will also include pharmacodynamic (PD), pharmacokinetic (PK), and health-related quality of life (HRQoL) measurements.
Timeline
- Start
- 2026-04-02
- Primary completion
- 2030-06-30
- Completion
- 2030-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QPI-1007 | Small interfering RNA (siRNA) | — | — |